Investigational drug · Phase 3
Monalizumab
Also called: IPH2201
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-small Cell Lung Cancer, Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
22
Any phase or sponsor naming "Monalizumab"
First trial start
2016
Feb 22, 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Monalizumab", any sponsor or status.
- Phase 218
Conditions studied
As listed on its trial records.
- Non-small Cell Lung Cancer
- Advanced Solid Tumors
- Squamous Cell Carcinoma of the Head and Neck
- Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Head and neck cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Monalizumab" as an intervention, largest first.
- A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05221840 · 1,051 participants · Start Feb 7, 2022 · Primary completion Jan 8, 2027
Drug: Durvalumab; Oleclumab and 1 more · For: Non-Small Cell Lung Cancer
Sites: San Diego, California; New Haven, Connecticut; Stuart, Florida · 202 sites in all
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT06769126 · 900 participants (planned) · Start Nov 6, 2025 · Primary completion Dec 31, 2028
Drug: Ceralasertib; Durvalumab and 4 more · For: Extensive Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma, A Subtype; Lung Small Cell Carcinoma, I Subtype and 2 more
Sites: Loma Linda, California; Rancho Mirage, California; Sacramento, California · 148 sites in all
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05061550 · 630 participants (planned) · Start Apr 14, 2022 · Primary completion May 28, 2030
Drug: Durvalumab; Oleclumab and 10 more · For: Non-small Cell Lung Cancer
Sites: Little Rock, Arkansas; Los Angeles, California; Oakland, California · 97 sites in all
- A Study of Durvalumab (MEDI4736) and Monalizumab in Solid TumorsPivotal-lookingActive, not recruiting
MedImmune LLCAstraZeneca (AZN)
NCT02671435 · 383 participants · Start Feb 22, 2016 · Primary completion Oct 26, 2021
Drug: Monalizumab; Durvalumab and 3 more · For: Advanced Solid Tumors
Sites: Birmingham, Alabama; Scottsdale, Arizona; Duarte, California · 49 sites in all
- Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04590963 · 370 participants · Start Oct 2, 2020 · Primary completion May 11, 2022
Drug: Monalizumab; Cetuximab · For: Squamous Cell Carcinoma of the Head and Neck
Sites: Tucson, Arizona; Chicago, Illinois; Westwood, Kansas · 127 sites in all
- Biomarker-based Study in R/M SCCHNStatus unknown
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT03088059 · 340 participants (planned) · Start Nov 16, 2017 · Primary completion Jun 2025
Drug: Afatinib; Palbociclib and 5 more · For: Carcinoma, Squamous Cell of Head and Neck
Sites: Brussels, Belgium; Charleroi, Belgium; Edegem, Belgium · 36 sites in all
- Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLCPivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT03822351 · 189 participants · Start Dec 19, 2018 · Primary completion Jul 18, 2023
Drug: Durvalumab + Oleclumab; Durvalumab and 1 more · For: Stage III Non-small Cell Lung Cancer; Unresectable
Sites: Anaheim, California; Duarte, California; Sacramento, California · 73 sites in all
Innate PharmaIndustry
NCT02643550 · 143 participants · Start Dec 2015 · Primary completion Mar 28, 2023
Drug: Monalizumab; Cetuximab and 1 more · For: Head and Neck Neoplasms
Sites: La Jolla, California; Stanford, California; Chicago, Illinois · 18 sites in all
- Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistancePivotal-lookingStatus unknown
Assistance Publique Hopitaux De MarseilleAcademic, hospital or other
NCT03833440 · 114 participants · Start Oct 8, 2019 · Primary completion Oct 2024
Drug: Durvalumab (MEDI4736); Monalizumab (IPH2201) and 4 more · For: Non-small Cell Lung Cancer
Sites: Marseille, France
- MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung CancerRecruiting
Khalil ChoucairAcademic, hospital or other
NCT05903092 · 84 participants (planned) · Start Sep 26, 2023 · Primary completion Oct 31, 2029
Drug: Durvalumab; Monalizumab and 2 more · For: Small Cell Lung Cancer; SCLC; Extensive Stage Small Cell Lung Cancer and 1 more
Sites: Indianapolis, Indiana; Iowa City, Iowa; Detroit, Michigan · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The HLA-E-NKG2A axis in breast cancer: an emerging NK-cell checkpoint and therapeutic target.
Li L, Han X, Lu L, et al. · Front Immunol 2026
- ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.
McGrath L, Kar G, Bonanno L, et al. · Nature 2026
- Radiotherapy and DNA damage response inhibitors modestly sensitize HNSCC to NK cell killing, with ATM inhibition more effective than ATR inhibition.
Steinsdörfer L, Zülch L, Schäfer A, et al. · Strahlenther Onkol 2026
- Natural killer cell immunotherapy reverses lung fibrosis by eliminating senescent fibroblasts.
Merkt W, Rodon L, Deicher FS, et al. · Sci Transl Med 2026
- The CD94/NKG2A-HLA-E Axis as a Target in Cancer Immunotherapy: A Critical Perspective.
López-Botet M, Vilches C, Muntasell A · Clin Cancer Res 2026
- Stochastic Gates for Covariate Selection in Population Pharmacokinetics Modeling.
Kekic M, Stepanov O, Wang W, et al. · CPT Pharmacometrics Syst Pharmacol 2026
Also in development for Non-small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.